Adult Height After Growth Hormone and Aromatase Inhibitor Therapy for Short Stature due to ACAN Mutation
AACE Endocrinology and Diabetes · 2026-07 · 13 (4) · 643-648
DOI: 10.1016/j.aed.2026.04.004 ↗Kurz gefasst
Fallbericht in der Zeitschrift AACE Endocrinology and Diabetes, 2026-07. Verfasst von Daniel Leopoldo Ruiz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Endocrinology and Diabetes, Rhode Island Hospital/Hasbro Children's Brown University Health, Providence, Rhode Island. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background/Objective Aggrecan ( ACAN ) deficiency is a cause of autosomal-dominant short stature, often accompanied by advanced bone age (BA) and early growth plate closure. Evidence for combined growth hormone (GH) plus aromatase inhibitor (AI) therapy in ACAN remains limited. Our objective is to report adult height in a child with a heterozygous ACAN variant who was treated with GH, followed by GH and AI during puberty. Case Presentation A boy was first evaluated at 2 years and 6 months for short stature, had markedly advanced BA by 5 years and 6 months, and a novel heterozygous frameshift ACAN variant. GH therapy was started at 6 years of age for short stature and BA advancement with compromised predicted adult height (PAH). AI was added to GH therapy when he entered central puberty at 11 years of age. After 4.5 years of combined therapies with GH and AI, he attained an adult height of 156.3 cm, which is 9 cm below his mid-parental target height but 14 cm above his pretreatment PAH. No AI-related adverse effects were reported.
Discussion
GH can improve growth velocity, and AIs may delay epiphyseal fusion by lowering estrogen conversion and thus extending the growth window. Our patient's height gain aligns with reported GH responses in ACAN and with data indicating that adjunctive AI can modestly increase PAH in boys with advanced BA.
Conclusion
This case highlights the potential benefits of combined GH and AI therapy in managing short stature in patients with ACAN mutation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pediatric Endocrinology and Diabetes, Rhode Island Hospital/Hasbro Children's Brown University Health, Providence, Rhode Island.
- Department of Pediatrics, Warren Alpert Medical School of Brown University, Providence, Rhode Island.
Zitieren
APA
Ruiz, D. L., Delano, A., & Quintos, J. B. (2026). Adult Height After Growth Hormone and Aromatase Inhibitor Therapy for Short Stature due to ACAN Mutation. AACE Endocrinology and Diabetes, 13(4), 643-648. https://doi.org/10.1016/j.aed.2026.04.004
Vancouver
Ruiz DL, Delano A, Quintos JB. Adult Height After Growth Hormone and Aromatase Inhibitor Therapy for Short Stature due to ACAN Mutation. AACE Endocrinology and Diabetes. 2026;13(4):643-648. doi:10.1016/j.aed.2026.04.004
BibTeX
@article{Ruiz2026,
author = {Ruiz, Daniel Leopoldo and Delano, Alexandra and Quintos, Jose Bernardo},
title = {Adult Height After Growth Hormone and Aromatase Inhibitor Therapy for Short Stature due to ACAN Mutation},
journal = {AACE Endocrinology and Diabetes},
year = {2026},
volume = {13},
number = {4},
pages = {643--648},
doi = {10.1016/j.aed.2026.04.004}
}
EUVIMED